Skip to content

Study · Non-randomized trial · 1987

4 results

Dopaminergic and cholinergic influences on the growth hormone response to growth hormone-releasing hormone in man.

Delitala G, Palermo M, Ross R, Coy D, Besser M, Grossman A

Neuroendocrinology1 Mar 1987Cited by 23 (Europe PMC)

PMID2882435 (opens in a new tab)DOI10.1159/000124732 (opens in a new tab)PepBankPUB-02882435
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In normal male subjects, GHRH(1-29)NH2 induced a rise in serum GH.

    In plain wordsIn healthy men, GHRH caused growth hormone in the blood to rise.

    Peptide
    Sermorelin
    Outcome
    IncreaseSerum GH rise after GHRH
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    GHRH(1-29)NH2 induced a rise in serum GH
    1 context sentence
    Summary · context
    We have, therefore, investigated the effect of a dopamine agonist, bromocriptine, and a dopamine antagonist, domperidone, as well as a muscarinic cholinergic antagonist, pirenzepine, on the GH response to an analogue of GH-releasing hormone (GHRH) in normal male subjects.

Studies that did not test the peptide alone3

In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Sermorelin.

  1. 02HumanNot a test of Sermorelin aloneNon-randomized trialMechanism

    In normal male subjects, the dopamine agonist bromocriptine augmented the GH response to GHRH.

    In plain wordsIn healthy men, bromocriptine increased the growth hormone response to GHRH.

    Peptide
    Sermorelin
    Outcome
    IncreaseGH response to GHRH with bromocriptine
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    augmented by bromocriptine
    1 context sentence
    Summary · context
    We have, therefore, investigated the effect of a dopamine agonist, bromocriptine, and a dopamine antagonist, domperidone, as well as a muscarinic cholinergic antagonist, pirenzepine, on the GH response to an analogue of GH-releasing hormone (GHRH) in normal male subjects.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  2. 03HumanNot a test of Sermorelin aloneNon-randomized trialMechanism

    In normal male subjects, the muscarinic antagonist pirenzepine antagonized the GH response to GHRH.

    In plain wordsIn healthy men, pirenzepine reduced the growth hormone response to GHRH.

    Peptide
    Sermorelin
    Outcome
    DecreaseGH response to GHRH with pirenzepine
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    antagonized by pirenzepine
    1 context sentence
    Summary · context
    We have, therefore, investigated the effect of a dopamine agonist, bromocriptine, and a dopamine antagonist, domperidone, as well as a muscarinic cholinergic antagonist, pirenzepine, on the GH response to an analogue of GH-releasing hormone (GHRH) in normal male subjects.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  3. 04HumanNot a test of Sermorelin aloneNon-randomized trialMechanism

    In normal male subjects, the dopamine antagonist domperidone did not alter the GH response to GHRH.

    In plain wordsIn healthy men, domperidone did not change the growth hormone response to GHRH.

    Peptide
    Sermorelin
    Outcome
    No significant changeGH response to GHRH with domperidone
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    but was unaltered by domperidone.
    1 context sentence
    Summary · context
    We have, therefore, investigated the effect of a dopamine agonist, bromocriptine, and a dopamine antagonist, domperidone, as well as a muscarinic cholinergic antagonist, pirenzepine, on the GH response to an analogue of GH-releasing hormone (GHRH) in normal male subjects.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.